ALT5 Sigma Corporation (ALTS)
NASDAQ: ALTS · Real-Time Price · USD
7.09
+0.52 (7.91%)
Aug 25, 2025, 1:09 PM - Market open

Company Description

ALT5 Sigma Corporation, together with its subsidiaries, provides blockchain-powered technologies worldwide.

It operates through Fintech and Biotechnology segments. The company engages in the tokenization, trading, clearing settlement, payment, and safe keeping of digital assets.

Its products include ALT 5 Prime, an electronic over-the-counter trading platform for the buying and selling of digital assets; and ALT 5 Pay, a crypto-currency payment gateway that enables merchants to accept and make crypto currency payments or integrate the payment platform into their application.

The company is also involved identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies for the treatment of pain and addiction.

In addition, it develops JAN 101, an oral and sustained-release pharmaceutical composition of sodium nitrite that has completed Phase 2a clinical trial to treat peripheral arterial disease and pain; and JAN123, a formulation of low-dose naltrexone for the treatment of chronic regional pain syndrome.

The company was formerly known as JanOne Inc. and changed its name to ALT5 Sigma Corporation in July 2024.

ALT5 Sigma Corporation was founded in 1976 and is based in Las Vegas, Nevada.

ALT5 Sigma Corporation
ALT5 Sigma logo
CountryUnited States
Founded1976
IndustrySoftware - Application
SectorTechnology
Employees10
CEOPeter Tassiopoulos

Contact Details

Address:
325 E. Warm Springs Road, Suite 102
Las Vegas, Nevada 89119
United States
Phone702 997 5968
Websitealt5sigma.com

Stock Details

Ticker SymbolALTS
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000862861
CUSIP Number74347B813
ISIN NumberUS47089W1045
Employer ID41-1454591
SIC Code2834

Key Executives

NamePosition
Peter TassiopoulosChief Executive Officer and Director
Tony IsaacPresident, Corporate Secretary, Treasurer and Director
Ron Michael PittersChief Operating Officer and Director
Jonathan HughChief Financial Officer
Matt MorganChief Investment Officer
Dr. Tony Giordano Ph.D.Chief Scientific Officer
Dr. Douglas Flanagan Ph.D.Chief Formulation Advisor
Vay ThamChief Revenue Officer

Latest SEC Filings

DateTypeTitle
Aug 19, 2025SCHEDULE 13GFiling
Aug 19, 2025SCHEDULE 13GFiling
Aug 18, 2025SCHEDULE 13GFiling
Aug 18, 20258-KCurrent Report
Aug 18, 2025SCHEDULE 13GFiling
Aug 12, 202510-QQuarterly Report
Aug 12, 20258-KCurrent Report
Aug 12, 202510-K/A[Amend] Annual report
Aug 11, 2025424B5Filing
Aug 11, 2025424B5Filing